MNPR stock news · Monopar Therapeutics Inc.
Get alerts for MNPR
Follow Monopar Therapeutics Inc. (MNPR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MNPRFree on the App Store and Google Play, or on the web.
Morgan Stanley still thinks highly of Monopar Therapeutics and its drug development plans.
NeutralMorgan Stanley kept its Overweight rating on Monopar Therapeutics. This repeats the firm's view without reporting a change in the company's business, so I read it as neutral.